Contact Us  I  Home 

Home

About The Epsilon Group

 

The Epsilon Group (TEG) combines contract research organization capabilities with strategic advisory services to formulate evidence-based strategy, identify market opportunities through research, and translate new knowledge into sales and market share.

 

TEG partners with clients to identify strategic research questions and design studies that will definitively answer clinical questions while enhancing the practice of medicine. Experience with real-world patient care combined with marketing insight allows TEG to design and implement studies that advance scientific knowledge and support a client’s long-term strategy.

 

With appropriate use of the latest technology, this data is acquired and analyzed quickly then professionally disseminated through our efficient technical and scientific communication strategies. The new information acquired is the basis for evidence-based clinician and consumer education to improve medical outcomes and increase our client’s market share.

 

Epsilon possesses the unique combination of clinical experience, scientific expertise, and strategic skills needed to identify your knowledge and data needs, profile your marketplace, and map a campaign to increase sales. We provide you with an evidence-based framework to move forward rapidly and decisively.

 

Our Philosophy

 

It is not enough to compile information and build knowledge – only when it is widely disseminated does knowledge build momentum for your product. And that is where TEG excels. We help you reach your target audience, from your sales force to clinicians to patients. And we craft just the right tools to reach them most effectively, from white papers and journal articles to lecture series and customized reports and presentations. Throughout, we emphasize evidence-based support as the driver of progress in healthcare.

Publications

 

Assessing Inpatient Glycemic Control: What Are the Next Steps? I Read

 

Update on Inpatient Glycemic Control in Hospitals in the United States I Read

 

Characterizing Glucose Changes Antecedent to Hypoglycemic Events in the ICU I Read

 

News

 

First FDA-Accepted Type 1 Diabetes Metabolic Simulator Now Available

Press Release  I  T1DM Product Page  I  T1DM Services Page

 

MAS-EPSILON Licenses SAAM II Software from the University of Washington Center for Commercialization

Press Release I SAAM II Website

© 2012 The Epsilon Group, An Alere Company, Charlottesville, VA USA. All rights reserved.